Trial Search Results

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

CRISPR Therapeutics AG


  • Biological: CTX130


Phase 1


Inclusion Criteria (abbreviated):

   1. Age ≥18 years.

   2. Confirmed diagnosis of a T cell malignancy or Diffuse Large B-Cell Lymphoma (DLBCL).

   3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

   4. Adequate renal, liver, cardiac, and pulmonary organ function.

   5. Female subjects of childbearing potential and male subjects must agree to use
   acceptable method(s) of contraception from enrollment through at least 12 months after
   CTX130 infusion.

Exclusion Criteria (abbreviated):

   1. Prior allogeneic stem cell transplant (SCT).

   2. Prior treatment with any anti-CD70 targeting agents.

   3. History of certain central nervous system (CNS), cardiac or pulmonary conditions.

   4. Active HIV, hepatitis B virus or hepatitis C virus infection.

   5. Previous or concurrent malignancy, except treated with curative approach not requiring
   systemic therapy and in remission for >12 months, or any other localized malignancy
   with low risk of developing into metastatic disease.

   6. Primary immunodeficiency disorder or active autoimmune disease requiring steroids
   and/or other immunosuppressive therapy.

   7. Prior solid organ transplantation.

   8. Pregnant or breastfeeding females.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Emma Crawford